Known targets — ChEMBL curated mechanism
ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3CHRM1CHRM2CHRM3CHRM4ESR1ESR2GABRA1GABRB1GABRG2GBA1HRH1HTR1DHTR2AOPRD1OPRK1OPRM1SLC6A2SLC6A3TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8rplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Ifenprodil. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA1A known ✓ | P35348 | 6/20 | 0.87 |
| ▸ | ADRA2A known ✓ | P08913 | 5/20 | 0.87 |
| ▸ | HTR2A known ✓ | P28223 | 5/20 | 0.87 |
| ▸ | ADRB1 known ✓ | P08588 | 1/20 | 0.87 |
| ▸ | ADRA2B known ✓ | P18089 | 1/20 | 0.87 |
| ▸ | ADRA2C known ✓ | P18825 | 1/20 | 0.87 |
| ▸ | SLC6A2 known ✓ | P23975 | 1/20 | 0.87 |
| ▸ | HRH1 known ✓ | P35367 | 1/20 | 0.87 |
| ▸ | OPRK1 known ✓ | P41145 | 1/20 | 0.87 |
| ▸ | SLC6A3 known ✓ | Q01959 | 1/20 | 0.87 |
| ▸ | ADRA1D known ✓ | P25100 | 1/20 | 0.62 |
| ▸ | ADRA1B known ✓ | P35368 | 1/20 | 0.62 |
| ▸ | GMNN | O75496 | 2/20 | 1.00 |
| ▸ | PMP22 | Q01453 | 1/20 | 1.00 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 1.00 |
| ▸ | GAA | P10253 | 1/20 | 1.00 |
| ▸ | GRIN2B | Q13224 | 7/20 | 0.87 |
| ▸ | GRIN1 | Q05586 | 5/20 | 0.87 |
| ▸ | HTR2B | P41595 | 4/20 | 0.87 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.87 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ifenprodil SCHEMBL1650040 | 1.00 | GMNN (1.00) | GMNNPMP22NPSR1GAAGRIN2B | |
| Ifenprodil SCHEMBL27730851 | 0.99 | GMNN (0.98) | GMNNPMP22NPSR1GAAGRIN2B | |
| (R,S)-Ifenprodil SCHEMBL12618846 | 0.93 | GRIN2B (1.00) | GMNNPMP22NPSR1GAAGRIN2B | |
| Ifenprodil SCHEMBL34010 | 0.93 | GRIN2B (1.00) | GMNNPMP22NPSR1GAAGRIN2B | |
| Ifenprodil SCHEMBL12496650 | 0.93 | GRIN2B (1.00) | GMNNPMP22NPSR1GAAGRIN2B | |
| (R,S)-Ifenprodil SCHEMBL21614195 | 0.93 | GRIN2B (1.00) | GMNNPMP22NPSR1GAAGRIN2B | |
| Ifenprodil SCHEMBL17654723 | 0.92 | GRIN2B (0.97) | GMNNPMP22NPSR1GAAGRIN2B | |
| Ifenprodil SCHEMBL11159184 | 0.92 | GRIN2B (0.97) | GMNNPMP22NPSR1GAAGRIN2B | |
| Ifenprodil SCHEMBL29237720 | 0.91 | GRIN2B (0.95) | GMNNPMP22NPSR1GAAGRIN2B | |
| Ifenprodil SCHEMBL26105078 | 0.90 | GRIN2B (0.85) | GMNNPMP22NPSR1GAAGRIN2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 824 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12605345-B2 | Transdermal drug delivery system | BioPhysics Pharma, Inc. (US) | 2026-04-21 | — | — | US | claimed |
| US-20250268841-A1 | Trans-Epithelial Membrane Drug Delivery System | Masiz, John J. (US) | 2025-08-28 | — | — | US | claimed |
| US-20250120907-A1 | Transmucosal Drug Delivery System | Masiz, John J. (US) | 2025-04-17 | — | — | US | claimed |
| US-12246098-B2 | Trans-epithelial membrane drug delivery system | BioPhysics Pharma, Inc. (US) | 2025-03-11 | — | — | US | claimed |
| US-12171752-B2 | Methods of treating post-COVID condition(s) | MEDICINOVA, INC. (US) | 2024-12-24 | — | — | US | claimed |
| EP-4472631-A1 | IBUDILAST FOR USE IN THE TREATMENT OF POST-COVID CONDITIONS | MediciNova, Inc. (US) | 2024-12-11 | — | — | EP | claimed |
| CN-118973574-A | Use of ibudilast for treating sequela of new coronaries pneumonia | 美迪诺亚公司 | 2024-11-15 | — | — | CN | claimed |
| US-20240216292-A1 | Trans-Epithelial Membrane Drug Delivery System | Masiz, John J. (US) | 2024-07-04 | — | — | US | claimed |
| US-20240108588-A1 | Transdermal Drug Delivery System | Masiz, John J. (US) | 2024-04-04 | — | — | US | claimed |
| WO-2024028324-A1 | MOLECULES FOR THE PREVENTION AND TREATMENT OF NEUROMUSCULAR DISORDERS | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (FR) | 2024-02-08 | — | — | WO | claimed |
| CN-101100453-A | Method for synthesizing ifenprodil tartrate | ZHONGQI PHARMACY TECHNOLOGY SH (CN) | 2008-01-09 | — | — | CN | claimed |
| EP-1829534-A1 | Use of compounds binding to the sigma receptor for the treatment of metabolic syndrome | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2007-09-05 | — | — | EP | claimed |
| CN-1988896-A | Use of compounds active on the sigma receptor for the treatment of mechanical allodynia | ESTEVE LABOR DR (ES) | 2007-06-27 | — | — | CN | claimed |
| EP-0580860-B2 | METHOD OF MANUFACTURING SOLID DISPERSION | NIPPON SHINYAKU CO LTD (JP) | 2004-12-15 | — | — | EP | claimed |
| US-5811547-A | Method for inducing crystalline state transition in medicinal substance | NIPPON SHINYAJU CO., LTD. (JP) | 1998-09-22 | — | — | US | claimed |
| US-5700410-A | Method of manufacturing wax matrices | NIPPON SHINYAKU CO., LTD. (JP) | 1997-12-23 | — | — | US | claimed |
| EP-0580860-B1 | METHOD OF MANUFACTURING SOLID DISPERSION | NIPPON SHINYAKU CO LTD (JP) | 1997-10-22 | — | — | EP | claimed |
| US-5288503-A | WATER-PERMEABLE DIFFUSION BARRIER OF POLYVINYL ALCOHOL | SRCHEM INCORPORATED (US) | 1994-02-22 | — | — | US | claimed |
| US-5260066-A | Cryogel bandage containing therapeutic agent | SRCHEM INCORPORATED (US) | 1993-11-09 | — | — | US | claimed |
| US-5145852-A | Vaso-active medicament to treat impotence | VIRAG RONALD (FR) | 1992-09-08 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12171752-B2 | Methods of treating post-COVID condition(s) | ACE, ACE2, ACER2 | ADRA1A 1679/4885ADRA2A 1134/4885HTR2A 1666/4885 |
| US-12605345-B2 | Transdermal drug delivery system | FABP2, VEGFA, CUTA | ADRA1A 159/4885ADRA2A 190/4885HTR2A 135/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.